An artificial intelligence solution for evaluation of prostate needle core biopsy specimens: impact in a non-specialist setting.

Gerald Niedobitek^1,2, Gernot Schmitz³, Manuel Fella³, André Oliveira³, John Theunissen⁴, Manuela Vecsler⁴, Jens Köllermann⁵

¹Institute for Pathology, Sana Klinikum Lichtenberg, Berlin, Germany. niedobitekg@gmail.com.

²Institut für Pathologie, Klinikum Ernst von Bergmann, Charlottenstr. 72, 14467, Potsdam, Germany. niedobitekg@gmail.com.

³Institute for Pathology, Sana Klinikum Lichtenberg, Berlin, Germany.

⁴Ibex Medical Analytics, Tel Aviv, Israel.

⁵Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt/M, Germany.

PubMed DOI

Abstract

The diagnosis of prostate cancer rests on the histopathological evaluation of prostate needle core biopsy specimens (NCBS) supplemented by immunohistochemistry as required. Because of the well-known interobserver variability in diagnosis and grading of prostate cancer, we have studied the capability of a commercially available artificial intelligence (AI) solution to aid in the diagnosis of PCa in…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.